What is the current stock price of Vaxcyte, Inc. (PCVX)?

As of the latest market data, Vaxcyte, Inc. (PCVX) is trading at $60.88. The stock has seen a loss of -1.31% today.

Does Vaxcyte, Inc. (PCVX) pay a dividend?

Based on current data, Vaxcyte, Inc. does not have a confirmed active dividend policy.

What is the market cap of Vaxcyte, Inc.?

The current market capitalization of Vaxcyte, Inc. (PCVX) is approximately unavailable.

PCVX

Vaxcyte, Inc.·Healthcare

60.88

1.313%(−0.81)

Market Closed

63.00

3.482%(+2.12)

After Hours

Last Updated: — ET

52W L: $28.0952W H: $65.00

PCVX NEWS

globenewswire.com

3d ago

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT.

globenewswire.com

Mar 23

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive® (PCV21) and Prevnar 20® (PCV20), the Current Standard-of-Care PCVs

globenewswire.com

Mar 18

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority Trial Expected in the Fourth Quarter of 2026

defenseworld.net

Mar 16

Bridgefront Capital LLC Increases Stock Holdings in Vaxcyte, Inc. $PCVX

Bridgefront Capital LLC boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 127.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,325 shares of the company's stock after buying an additional 13,617 shares during the period. Bridgefront Capital

defenseworld.net

Mar 1

Citigroup Inc. Sells 116,206 Shares of Vaxcyte, Inc. $PCVX

Citigroup Inc. reduced its stake in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 27.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 313,078 shares of the company's stock after selling 116,206 shares during the period. Citigroup Inc. owned approximately 0.24% of Vaxcyte worth $11,277,000 as

seekingalpha.com

Feb 24

Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript

Company Profile

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Sector

Healthcare

Industry

Biotechnology

Employees

414

IPO Date

2020-06-12

Beta

1.39

Websitevaxcyte.com↗